MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/clinem/dgag051

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2026

Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer.

Patrizio Armando, Mauguen Audrey, Fagin James A, Farooki Azeez, Fish Stephanie S, Flory James, Newman Samantha, Presswala Lubaina, Sabra Mona M, Tuttle R Michael, Boucai Laura

СтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

CONTEXT: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) benefit patients with diabetes mellitus (DM) and obesity. While contraindicated in medullary thyroid cancer, their effect in well-differentiated thyroid cancer (DTC) remains poorly understood.

OBJECTIVE

To determine the impact of GLP-1RAs on the risk of DTC recurrence/progression.

DESIGN AND

SETTING

Retrospective observational cohort study at a tertiary care center in New York.

PARTICIPANTS, INTERVENTION, AND MAIN OUTCOME: Five hundred thirty-six patients with DTC exposed to GLP-1RA were matched 1:1 to 536 patients with DTC never exposed to GLP-1RA by age, date of DTC diagnosis, TNM stage, body mass index (BMI), and DM. A multistate model enabled us to assess the impact of GLP-1RA as a time-dependent variable on the transition of patients with DTC from a "no/stable disease" state to a "recurrence/progression" state.

RESULTS

A total of 1072 patients, median age 49, 71% females, 54% with DM, mean BMI ± SD 35 ± 7 kg/m², 84% with American Joint Committee on Cancer stage I disease, 58% with American Thyroid Association (ATA) intermediate or high risk of recurrence, with median GLP-1RA exposure of 16 months were followed for a median of 69 months. GLP-1RA use was not significantly associated with recurrence or progression of disease in the survival cohort [hazard ratio (HR) = 0.87, 95% confidence interval (CI) 0.62-1.21, P = .39) or the entire cohort (HR = 0.75, 95% CI 0.54-1.03, P = .07) on a multivariable model adjusted for age, ATA risk, radioactive iodine therapy, and DM.

CONCLUSION

We did not find GLP-1RA to be significantly associated with recurrent/progressive DTC. Eligible patients with DTC should not be denied the cardiometabolic benefits of GLP-1RA when clinically indicated.

Для цитирования: Patrizio Armando, Mauguen Audrey, Fagin James A, Farooki Azeez, Fish Stephanie S, Flory James, Newman Samantha, Presswala Lubaina, Sabra Mona M, Tuttle R Michael, Boucai Laura. Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer.. The Journal of clinical endocrinology and metabolism. 2026. DOI: 10.1210/clinem/dgag051.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.